Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
John and James of Aster funds ltd Canadian 11387863
Corporation NameAster Funds Ltd.
Business No.796210276RC0001
Date of IncorporationCanada Business Corporations Act - 2019-05-02
Record StatusActive
TypeNon-distributing corporation with 50 or fewer shareholders
Certificates and FilingsCertificate of Incorporation 2019-05-02
Russia still attracting investments
Moscow, December 22, 2022 - PJSC «MMC «Norilsk Nickel», world’s largest palladium and high-grade nickel producer, as well as one of the leading platinum and copper producers, announces successful placement of CNY 5 bln (~USD710mm) exchange-traded bonds (series ??-001?-06-CNY) on December 22, 2022. The deal is an essential step in the development of the public debt market for corporates – it is the first ever CNY placement at a floating interest rate in the Russian bond market history. The coupon rate is based on Loan Prime Rate (1Y), that is calculated by National Interbank Funding Center (NIFC) as arythmetic average of loan rates quoted by 16 Chinese banks and 2 international banks for the loans extended to corporate borrowers of the highest credit quality.
Email sent, auto reply received by Hurricane and Jacob.
Two positive posts from Richard and baking. Sorry if already posted .
https://twitter.com/RichardDugdale3/status/1541669869254582272?s=20&t=AyObeWyTZ32xDHOklJeKzA
https://twitter.com/TheBakingTrader/status/1541669958211588096?s=20&t=AyObeWyTZ32xDHOklJeKzA
Russia’s Nornickel on Monday cut its estimate for the global palladium market deficit in 2022 to 100,000 troy ounces due to lower demand from the car industry amid the Ukraine crisis and a slow recovery of the chip market from shortage.
Western sanctions imposed on Moscow after it sent tens of thousands of troops into Ukraine on Feb. 24 have not so far targeted Nornickel, the world’s largest producer of palladium and high-grade nickel.
SIGN UP FOR THE PRECIOUS METALS DIGEST
Nornickel, which accounts for 40% of the global palladium primary production, “continues to deliver metals according to its contract obligations despite logistic obstacles associated with limited availability of international flights” from Russia, it said in its updated market review.
“Russian nickel exports have not been affected, and Nornickel continues to fulfil all contractual obligations,” the miner added.
Nornickel, which accounts for 20% of high-grade nickel production, said excluding Russian nickel from the trade system would be disastrous for the London Metals Exchange and the global nickel market.
The company now expects the global nickel market surplus of 37,000 tonnes in 2022 before it widens to 103,000 tonnes of nickel – mainly of low-grade nickel – in 2023 due to the start of new production capacity in Indonesia.
The palladium market would remain in balance in 2023 as the recovery in the auto demand would be mostly offset by rising supply, the miner added.
In February, the miner forecast a global palladium market deficit of 300,000 ounces and the global nickel market surplus of 42,000 tonnes in 2022.
https://www.mining.com/kinross-gold-sells-russian-assets-to-highland-for-680-million/
Let’s see if Moscow allows
BRICS is the acronym coined to associate five major emerging economies: Brazil, Russia, India, China, and South Africa. The BRICS members are known for their significant influence on regional affairs. Since 2009, the governments of the BRICS states have met annually at formal summits. India
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
February 4, 2022 at 7:00 AM EST
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced submission of an amendment to an Investigational New Drug (IND) application for evaluation of orally administered capsules of foralumab, which it believes would be the first “take home” immunotherapy, in patients with mild-to-moderately active Crohn’s Disease. If accepted by the U.S. Food and Drug Administration (FDA), the amendment is expected to expedite patient enrollment and completion of the foralumab Phase 1b study by the fourth quarter of 2022.
The currently planned Phase 1b study with an amended protocol is designed as a placebo-controlled, randomized and dose-escalating trial, in mild-to-moderate patients with Crohn’s Disease. The patients will be dosed up to 5 mg once daily for five consecutive days and safety of patients will be monitored throughout the treatment period in the hospital or clinical research unit (CRU). The primary objective of this study is to determine safety and tolerability. The study will also evaluate the pharmacodynamic (PD) effects on modulation of immunobiomarkers, including calprotectin, a widely used biomarker for gut inflammation, in stools, as a secondary endpoint. Data from an earlier Phase 1a, single-ascending dose (SAD) study with orally administered foralumab in healthy volunteers determined that the treatment was well-tolerated up to 5 mg, which was the highest dose tested.
This amendment would allow for the investigation of a broader patient population as well as a shorter dosing period. Previously, Tiziana had submitted an IND to conduct a Phase 1b study in moderate-to-severe active Crohn’s Disease patients to evaluate safety of enteric-coated foralumab capsules administered orally once daily for 14 days as an inpatient study in the hospital or CRU with safety monitoring, for which the FDA issued a ‘Study May Proceed letter’. However, initial feasibility findings indicated that enrollment of patients in this initial safety study, requiring 14-day hospitalization, was highly challenging due to the COVID-19 pandemic. Thus, the clinical protocol has been amended to expedite patient enrollment and study completion.
The clinical findings from this Phase 1b study could support moving foralumab into a Phase 2 clinical trial in patients with mild-to-moderate Crohn’s Disease. Tiziana is awaiting FDA’s comments on the amended TILS-014 protocol and, with clearance of the amendment, anticipates completing the Phase 1b study by the fourth
We need a new leader with appositive outlook for the future of Hurricane.
From the Court Hearing Result 28th June 2021.
The existing Hurricane board is considering all options, including an appeal. Unless the Company or the Ad Hoc Committee successfully appeals the judgment, the Restructuring Plan will not be implemented. The Company's convertible bondholders have certain rights under the terms of the convertible bonds which, if enforced, could result in an acceleration of the convertible bonds and ultimately an insolvent liquidation of the Company. As a result there is a significant risk of no value being returned to shareholders.
I had same reply
For all our genuine investors
https://www.youtube.com/hashtag/nevergonnagiveyouup
They been talking with the authorities for over 4 years
https://www.youtube.com/watch?v=VFpG4yqlJg
just over 4 years ago
https://www.bing.com/search?q=tip+tv+mining+bytheway&form=ANNTH1&refig=342ed45f210e4633b2b713ea7f74bc2e#
https://mobile.twitter.com/hashtag/Eurasiamining?src=hashtag_click
R1EX Every vote Matters